Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The primary objective of this study is to evaluate whether cilofexor reduces the risk of
fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Hepatitis B
Enrollment Eligibility
Key Inclusion Criteria:
- Diagnosis of large duct PSC
- Liver biopsy at screening that is deemed acceptable for interpretation and
demonstrates stage F0 - F3 fibrosis in the opinion of the central reader
- Individual has the following laboratory parameters at the screening visit, as
determined by the central laboratory:
- Platelet count ≥ 150,000/mm^3
- Estimated glomerular filtration rate (eGFR) ≥ 30 milliliter/minute (mL/min), as
calculated by the Cockcroft-Gault equation
- ALT ≤ 8 x upper limit of the normal range (ULN)
- Total bilirubin < 2 mg/dL, unless the individual is known to have Gilbert's
syndrome or hemolytic anemia
- International normalized ratio (INR) ≤ 1.4, unless due to therapeutic
anticoagulation
- Negative anti-mitochondrial antibody
Key Exclusion Criteria:
- Current or prior history of any of the following:
- Cirrhosis
- Liver transplantation
- Cholangiocarcinoma or hepatocellular carcinoma (HCC)
- Ascending cholangitis within 30 days of screening
- Presence of a percutaneous drain or biliary stent
- Other causes of liver disease
- Current or prior history of unstable cardiovascular disease
- Current moderate to severe inflammatory bowel disease (IBD) (including ulcerative
colitis, Crohn's disease, and indeterminate colitis)
Note: Other protocol defined Inclusion/Exclusion criteria may apply